CPMDOTCPharmaceutical PreparationsFiscal year ends December 31
CANNAPHARMARX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.00+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $1.36M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0019 (−48.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
CANNAPHARMARX, INC. grew revenue 24.8% to $1.70M over the twelve months to Jun 30, 2026. Free cash flow was -$794.62K.
Revenue
$1.70M
+24.8% vs. a year earlier
Operating income
-$2.89M
TTM Q2 2026
Free cash flow
-$794.62K
FY2025
EPS, diluted
-$0.02
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.36M
- P/E ratio
- –
- Price to sales
- 0.80
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -58.22%
Fundamentals
- Revenue
- $1.70M
- Net income
- -$11.32M
- EPS, diluted
- -$0.02
- Free cash flow
- -$794.62K
- Book value per share
- -$0.05
- Diluted shares
- 682M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.70M+24.8% YoY
Gross profit
-$1.51M
Operating income
-$2.89M
Net income
-$11.32M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months